type 2 diabetes glp-1 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Why can't we use GLP-1s
Description
2022 Apr 12;27(8):2478
In rare cases, stuck food hardens into solid masses called bezoars, which can cause blockages
The GLP-1 analogues drugs class is now being studied for its potential in the treatment of other indications such as NASH (nonalcoholic steatohepatitis), Alzheimers disease, Obstructive Sleep Apnea (OSA) and several cardiovascular indications
Eligibility screening ensures that only patients who are medically appropriate for GLP-1s move forward
Our approach is rooted in science, safety, and long-term results
